tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keratosis, Actinic D055623 3 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Abou-Jaoude MM et al. Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients. 2003 Transplant. Proc. pmid:14612103
Havrdova T et al. Effect of tacrolimus versus cyclosporine on glucose metabolism of pancreas and kidney recipients in the late (> 8 years) posttransplant period. 2011 Transplant. Proc. pmid:22099774
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Guitard J et al. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. 2007 Transplant. Proc. pmid:17954189
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Undre NA et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. 1998 Transplant. Proc. pmid:9636527
Park K et al. Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study. 2000 Transplant. Proc. pmid:11119901
Gruessner RW et al. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. 1998 Transplant. Proc. pmid:9532156
Rahamimov R et al. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol. 2003 Transplant. Proc. pmid:12644082
Gavela Martínez E et al. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression. 2009 Jul-Aug Transplant. Proc. pmid:19715913
Hayashi S et al. Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). 1997 Transplant. Proc. pmid:9193595
Sgrosso JL et al. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine. 2002 Transplant. Proc. pmid:11959214
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Charpentier B An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. 2001 Transplant. Proc. pmid:11406262
Weir MR Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. 2001 Transplant. Proc. pmid:11406264
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
Nakamura M et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. 1998 Transplant. Proc. pmid:9636600
Imamura M et al. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. 2000 Transplant. Proc. pmid:11120238
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Forsythe J Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. 1999 Transplant. Proc. pmid:10576049
Bilodeau JF et al. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. 2009 Transplant. Proc. pmid:19917367
Resch B et al. FK 506 and successful pregnancy in a patient after renal transplantation. 1998 Transplant. Proc. pmid:9474990
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Moscicka M et al. The effect of cyclosporine and tacrolimus on indigenous bacterial flora in human skin grafts. 2003 Transplant. Proc. pmid:14529942
Kim HC et al. Primary immunosuppression with tacrolimus in renal transplantation: a single center experience. 2003 Transplant. Proc. pmid:12591370
Tada H et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. 2005 Transplant. Proc. pmid:15919447
Borrows R et al. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. 2005 Transplant. Proc. pmid:15919448
Hodge EE et al. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. 2002 Transplant. Proc. pmid:12176477
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Ahlmén J et al. Positive effects of tacrolimus in a case of CIDP. 1998 Transplant. Proc. pmid:9865344
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Cicero A and Lappin JA Pancreas transplantation: experience at University of Texas, Houston. 2010 Jan-Feb Transplant. Proc. pmid:20172339
Barten MJ et al. Pharmacodynamics of the immunosuppressive effects of the combination of tacrolimus with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12270442
Forgacs B et al. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. 2005 Transplant. Proc. pmid:15919502
Gaber LW et al. Renal histology with varying FK506 blood levels. 1997 Feb-Mar Transplant. Proc. pmid:9122955
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Yoshimura N et al. Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients. 2002 Transplant. Proc. pmid:12176501
De Paolis P et al. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. 2011 Transplant. Proc. pmid:21620039
Renner FC et al. Tacrolimus intoxication resolved by gastrointestinal bleeding: case report. 2007 Transplant. Proc. pmid:17362773
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Sho M et al. Simultaneous inoculation of donor lymphocyte subsets with transplantation in a rat cardiac allograft model. 1998 Transplant. Proc. pmid:9838696
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Kramer MR et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). 1997 Transplant. Proc. pmid:9290780
Tashiro H et al. Correlation of high-level microchimerism with graft acceptance in rat liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123287
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Wijnen RM et al. Thymus atrophy in the nonhuman primate by FK506: an immunohistochemical study. 1997 Feb-Mar Transplant. Proc. pmid:9123292
Ierardi E et al. Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. 2001 Transplant. Proc. pmid:11377467
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Bilbao I et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. 2001 Transplant. Proc. pmid:11377472
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
van Duijnhoven EM et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. 2002 Transplant. Proc. pmid:12176552
Uchida J et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. 2012 Transplant. Proc. pmid:22310596
Chen YB et al. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population. 2011 Transplant. Proc. pmid:21693271
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Reutzel-Selke A et al. Donor pretreatment of grafts from marginal donors improves long-term graft outcome. 2001 Feb-Mar Transplant. Proc. pmid:11267150
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Mabuchi M et al. Insulin-like growth factor-I enhances choleretic action of FK506 in rats. 2003 Transplant. Proc. pmid:12826230
Lemahieu WP et al. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. 2005 Transplant. Proc. pmid:15964336
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. 1998 Transplant. Proc. pmid:9723303
McLaughlin GE et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. 2000 Transplant. Proc. pmid:10812158
Lo A et al. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. 2003 Transplant. Proc. pmid:12742477
Polanco N et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant. Proc. pmid:25645770
El-Sabrout R et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176636
Staak A et al. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. 2006 Transplant. Proc. pmid:17175311
Moray G et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. 2006 Transplant. Proc. pmid:17175334
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
Rayhill SC et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. 2006 Transplant. Proc. pmid:17175350
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Nojima M et al. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function. Transplant. Proc. pmid:28104155
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Jain A et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. 2001 Feb-Mar Transplant. Proc. pmid:11267319
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Percy C et al. Impact of Acute Infection Requiring Hospitalization on Tacrolimus Blood Levels in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:29149962
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Torregrosa JV et al. Combined liver-kidney transplantation: our experience. 1999 Transplant. Proc. pmid:10500591
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Fischer S et al. Initial experience of combined immunosuppressive induction therapy with polyclonal antithymocyte antibody, FK 506 (tacrolimus), and prednisolone in clinical liver transplantation. 2000 Transplant. Proc. pmid:11134815
Kelley M et al. Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. 2005 Transplant. Proc. pmid:16213338
Hashi S et al. Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. 2014 Transplant. Proc. pmid:24767342
García-Bello JA et al. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. 2016 Transplant. Proc. pmid:27110020
Takahashi K et al. Tacrolimus therapy for ABO-incompatible kidney transplantation. 1998 Transplant. Proc. pmid:9636495
Kanatani T et al. Experimental limb transplantation, part III: induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. 2004 Transplant. Proc. pmid:15686745